Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 254

Sort by

Sort Order Select

Journal Articles

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Charlotte FM Hughes, Richard J. Lin, Sean M. Devlin, Brian C. Shaffer, Ann A. Jakubowski, Vishwamber Talla, Amethyst Saldia, Boglarka Gyurkocza, Esperanza B. Papadopoulos, Sergio A. Giralt, Elena Maryamchik, Miguel-Angel Perales, Roni Tamari

Blood (2024) 144 (Supplement 1): 267.

https://doi.org/10.1182/blood-2024-198799

Published: 2024

Journal Articles

Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies

Richard J. Lin, Soo Jung Kim, Samantha Brown, Danielle M Hanley, Danielle E Engstler, Ioannis Politikos, Boglarka Gyurkocza, Roni Tamari, Esperanza B. Papadopoulos, Amethyst Saldia, Yetunde Aremu, Aaron D. Goldberg, Mark Blaine Geyer, Eytan M. Stein, Miguel Angel Perales, Beatriz Korc-Grodzicki, Sean M. Devlin, Sergio A. Giralt

Blood (2024) 144 (Supplement 1): 686.

https://doi.org/10.1182/blood-2024-207934

Published: 2024

Journal Articles

Belantamab Mafodotin , nirogacestat and Pomalidomide for Patients with Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7077.

https://doi.org/10.1182/blood-2024-211857

Published: 2024

Journal Articles

Prospective Feasibility Trial of Pharmacokinetic Directed Melphalan for Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Charlotte FM Hughes, Andrew Lin, Maria Bromberg, Sean M. Devlin, Amethyst Saldia, Danielle E Engstler, Danielle M Hanley, Yetunde Aremu, Martin Donach, Elizabeth Hoover, Oscar B Lahoud, Arnab Ghosh, Moneeza Walji, Miguel-Angel Perales, Michael Scordo, Sergio A. Giralt, Gunjan L. Shah, Parastoo B Dahi

Blood (2024) 144 (Supplement 1): 6492.

https://doi.org/10.1182/blood-2024-208310

Published: 2024

Journal Articles

Infectious Complications during Treatment with Commercial CAR T-Cell Therapy and Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 6935.

https://doi.org/10.1182/blood-2024-207977

Published: 2024

Journal Articles

Defining the Rates of Cytokine Release Syndrome Associated with Talquetamab Step-up Doses

Blood (2024) 144 (Supplement 1): 6990.

https://doi.org/10.1182/blood-2024-209891

Published: 2024

Journal Articles

Treatment Patterns of Immunoglobulin Replacement Therapy Among Patients with Multiple Myeloma in the United States: A Real-World Analysis

Fidelia Ida, Bharat Ramakrishna, Kaz Nasserinejad, Adriana Radu, John-Philip Lawo, Xiang Zhang, David Gardiner, Lara Yoon, John Shen, Elizabeth C. Dabrowski, Saarah Khan, Gabriela Espinoza, Zainab Shahid, Sergio A. Giralt

Blood (2024) 144 (Supplement 1): 6989.

https://doi.org/10.1182/blood-2024-206999

Published: 2024

Journal Articles

Comparison of Acute Kidney Injury in Patients with Relapsed or Refractory Multiple Myeloma Following CAR T-Cell and Bispecific Antibody Therapies

Blood (2024) 144 (Supplement 1): 6944.

https://doi.org/10.1182/blood-2024-212006

Published: 2024

Journal Articles

Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma - Interim Efficacy Results of a Randomized Clinical Trial

Blood (2024) 144 (Supplement 1): 3362.

https://doi.org/10.1182/blood-2024-208094

Published: 2024

Journal Articles

Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2024) 144 (Supplement 1): 1944.

https://doi.org/10.1182/blood-2024-208490

Published: 2024

Journal Articles

Infections in Patients with Relapsed/Refractory Multiple Myeloma in the United States: A Real-World Analysis

Fidelia Ida, Bharat Ramakrishna, Kaz Nasserinejad, Adriana Radu, John-Philip Lawo, Xiang Zhang, David Gardiner, Lara Yoon, Elizabeth C. Dabrowski, John Shen, Monica Iyer, Hannah Kreisberg, Gabriela Espinoza, Zainab Shahid, Sergio A. Giralt

Blood (2024) 144 (Supplement 1): 3346.

https://doi.org/10.1182/blood-2024-205221

Published: 2024

Journal Articles

Manufacture of Anti-BCMA CAR T Cell Is Feasible after Salvage Autologous or Allogeneic Hematopoietic Stem Cell Transplantation

Gunjan L. Shah, Karlo Perica, Katherine Nagel, Erica Payson, Kinga K. Hosszu, David J. Chung, Heather J. Landau, Michael Scordo, Malin Hultcrantz, Neha Korde, Kylee H Maclachlan, Urvi A. Shah, Carlyn Rose Tan, Hamza Hashmi, Alexander M. Lesokhin, Sridevi Rajeeve, Saad Z. Usmani, Sham Mailankody, Sergio A. Giralt

Blood (2024) 144 (Supplement 1): 4850.

https://doi.org/10.1182/blood-2024-212230

Published: 2024

Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Blood (2023) 142 (Supplement 1): 469.

https://doi.org/10.1182/blood-2023-182177

Published: 2023

Journal Articles

Successful Incorporation of Electronic Patient Reported Outcomes Using Promis-29 into Standard of Care after Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T Cell Therapy

Gunjan L. Shah, Stephanie Lobaugh, Ranjit Sukhu, Sean M. Devlin, Thomas Atkinson, Elizabeth Kemeny, Peter Stetson, Miguel-Angel Perales, Sergio A. Giralt, Michael Scordo

Blood (2023) 142 (Supplement 1): 7382.

https://doi.org/10.1182/blood-2023-179330

Published: 2023

Journal Articles

First Fever between Lymphodepletion and Day 30 after CAR-T Cell Therapy: Patterns, Origins, and Implications in Lymphoma Patients

Blood (2023) 142 (Supplement 1): 6907.

https://doi.org/10.1182/blood-2023-181999

Published: 2023

Journal Articles

Evaluating the Effect of Evolving Changes in Serum Biomarkers on the Risk of Progression in Smoldering Multiple Myeloma

Blood (2023) 142 (Supplement 1): 877.

https://doi.org/10.1182/blood-2023-180315

Published: 2023

Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Blood (2023) 142 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2023-187433

Published: 2023

Journal Articles

Low Target Antigen Expression Mediates Resistance to BCMA CAR T Cell Therapy

Karlo Perica, Sarah Nataraj, Maria Lemdal Sjojstrand, Katherine Nagel, Emma Pavkovic, Erica Payson, Ana Cuenca, Anjali Patel, David Chung, Sham Mailankody, Gunjan L. Shah, Saad Z Usmani, Sergio A. Giralt, Michel Sadelain

Blood (2023) 142 (Supplement 1): 2124.

https://doi.org/10.1182/blood-2023-178954

Published: 2023

Journal Articles

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

Michel Delforge, Krina K. Patel, Laurie Eliason, Devender Dhanda, Ling Shi, Shien Guo, Thomas S. Marshall, Bertrand Arnulf, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Sergio A. Giralt, Hermann Einsele, Sikander Ailawadhi, Mihaela Popa-McKiver, Mark Cook, Paula Rodriguez Otero

Blood (2023) 142 (Supplement 1): 96.

https://doi.org/10.1182/blood-2023-179152

Published: 2023

Journal Articles

Evaluating Tumor-Intrinsic and Patient-Specific Mechanisms of Resistance to Teclistamab in Anti-BCMA Exposed and Naïve Multiple Myeloma

Blood (2023) 142 (Supplement 1): 333.

https://doi.org/10.1182/blood-2023-187467

Published: 2023

NARROW

Long-Term Follow up of a Prospective Pilot Study of an α/β T-Lymphocyte Depleted Graft Conditioned with a Reduced Intensity Regimen in Patients with Hematologic Malignancies

Phase II Study of Longitudinal Geriatric Assessment with Risk-Adapted Interventions to Reduce Non-Relapse Mortality in Allogeneic Hematopoietic Cell Transplantation for Older Patients with Advanced Myeloid Malignancies

Belantamab Mafodotin , nirogacestat and Pomalidomide for Patients with Relapsed/Refractory Multiple Myeloma

Prospective Feasibility Trial of Pharmacokinetic Directed Melphalan for Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation

Infectious Complications during Treatment with Commercial CAR T-Cell Therapy and Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

Defining the Rates of Cytokine Release Syndrome Associated with Talquetamab Step-up Doses

Treatment Patterns of Immunoglobulin Replacement Therapy Among Patients with Multiple Myeloma in the United States: A Real-World Analysis

Comparison of Acute Kidney Injury in Patients with Relapsed or Refractory Multiple Myeloma Following CAR T-Cell and Bispecific Antibody Therapies

Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma - Interim Efficacy Results of a Randomized Clinical Trial

Impact of Absolute Lymphocyte Count at Pre-Apheresis and Pre-Lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)

Infections in Patients with Relapsed/Refractory Multiple Myeloma in the United States: A Real-World Analysis

Manufacture of Anti-BCMA CAR T Cell Is Feasible after Salvage Autologous or Allogeneic Hematopoietic Stem Cell Transplantation

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Successful Incorporation of Electronic Patient Reported Outcomes Using Promis-29 into Standard of Care after Hematopoietic Stem Cell Transplant and Chimeric Antigen Receptor T Cell Therapy

First Fever between Lymphodepletion and Day 30 after CAR-T Cell Therapy: Patterns, Origins, and Implications in Lymphoma Patients

Evaluating the Effect of Evolving Changes in Serum Biomarkers on the Risk of Progression in Smoldering Multiple Myeloma

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Low Target Antigen Expression Mediates Resistance to BCMA CAR T Cell Therapy

Effects of Idecabtagene Vicleucel (Ide-Cel) Versus Standard Regimens on Health-Related Quality of Life (HRQoL) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Had Received 2-4 Prior Regimens: Updated Results from the Phase 3 KarMMa-3 Trial

Evaluating Tumor-Intrinsic and Patient-Specific Mechanisms of Resistance to Teclistamab in Anti-BCMA Exposed and Naïve Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only